Allergy Therapeutics Statistics
Total Valuation
AGYTF has a market cap or net worth of 408.35 million. The enterprise value is 438.69 million.
| Market Cap | 408.35M |
| Enterprise Value | 438.69M |
Important Dates
The next estimated earnings date is Friday, June 27, 2025.
| Earnings Date | Jun 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +180.43% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 222.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.86 |
| PB Ratio | -45.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.83 |
| EV / Sales | 5.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.91 |
Financial Position
The company has a current ratio of 1.60
| Current Ratio | 1.60 |
| Quick Ratio | 1.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.39 |
| Interest Coverage | -8.01 |
Financial Efficiency
Return on equity (ROE) is -369.20% and return on invested capital (ROIC) is -48.41%.
| Return on Equity (ROE) | -369.20% |
| Return on Assets (ROA) | -25.11% |
| Return on Invested Capital (ROIC) | -48.41% |
| Return on Capital Employed (ROCE) | -61.31% |
| Revenue Per Employee | 113,854 |
| Profits Per Employee | -72,927 |
| Employee Count | 612 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +310.00% in the last 52 weeks. The beta is 1.23, so AGYTF's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +310.00% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.49 |
| Average Volume (20 Days) | 16,019 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AGYTF had revenue of 69.68 million and -44.63 million in losses. Loss per share was -0.01.
| Revenue | 69.68M |
| Gross Profit | 37.66M |
| Operating Income | -35.72M |
| Pretax Income | -44.58M |
| Net Income | -44.63M |
| EBITDA | -33.23M |
| EBIT | -35.72M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 27.14 million in cash and 55.73 million in debt, giving a net cash position of -28.60 million.
| Cash & Cash Equivalents | 27.14M |
| Total Debt | 55.73M |
| Net Cash | -28.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -8.95M |
| Book Value Per Share | -0.00 |
| Working Capital | 19.70M |
Cash Flow
In the last 12 months, operating cash flow was -36.39 million and capital expenditures -3.83 million, giving a free cash flow of -40.22 million.
| Operating Cash Flow | -36.39M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -40.22M |
| FCF Per Share | n/a |
Margins
Gross margin is 54.04%, with operating and profit margins of -51.27% and -64.05%.
| Gross Margin | 54.04% |
| Operating Margin | -51.27% |
| Pretax Margin | -63.98% |
| Profit Margin | -64.05% |
| EBITDA Margin | -47.69% |
| EBIT Margin | -51.27% |
| FCF Margin | n/a |
Dividends & Yields
AGYTF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -180.43% |
| Shareholder Yield | -180.43% |
| Earnings Yield | -10.93% |
| FCF Yield | -9.85% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AGYTF has an Altman Z-Score of -2.78. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.78 |
| Piotroski F-Score | n/a |